Suppr超能文献

Spitz 黑色素瘤是 Spitz 样黑色素瘤的一个独特亚型。

Spitz melanoma is a distinct subset of spitzoid melanoma.

机构信息

Department of Pathology, Stanford University, Stanford, CA, USA.

Departments of Pathology and Dermatology, University of California San Francisco, San Francisco, CA, USA.

出版信息

Mod Pathol. 2020 Jun;33(6):1122-1134. doi: 10.1038/s41379-019-0445-z. Epub 2020 Jan 3.

Abstract

Melanomas that have histopathologic features that overlap with those of Spitz nevus are referred to as spitzoid melanomas. However, the diagnostic concept is used inconsistently and genomic analyses suggest it is a heterogeneous category. Spitz tumors, the spectrum of melanocytic neoplasms extending from Spitz nevi to their malignant counterpart Spitz melanoma, are defined in the 2018 WHO classification of skin tumors by the presence of specific genetic alterations, such as kinase fusions or HRAS mutations. It is unclear what fraction of "spitzoid melanomas" defined solely by their histopathologic features belong to the category of Spitz melanoma or to other melanoma subtypes. We assembled a cohort of 25 spitzoid melanomas diagnosed at a single institution over an 8-year period and performed high-coverage DNA sequencing of 480 cancer related genes. Transcriptome wide RNA sequencing was performed for select cases. Only nine cases (36%) had genetic alterations characteristic of Spitz melanoma, including HRAS mutation or fusion involving BRAF, ALK, NTRK1, or MAP3K8. The remaining cases were divided into those with an MAPK activating mutation and those without an MAPK activating mutation. Both Spitz melanoma and spitzoid melanomas in which an MAPK-activating mutation could not be identified tended to occur in younger patients on skin with little solar elastosis, infrequently harbored TERT promoter mutations, and had a lower burden of pathogenic mutations than spitzoid melanomas with non-Spitz MAPK-activating mutations. The MAPK-activating mutations identified affected non-V600 residues of BRAF as well as NRAS, MAP2K1/2, NF1, and KIT, while BRAF V600 mutations, the most common mutations in melanomas of the WHO low-CSD category, were entirely absent. While the "spitzoid melanomas" comprising our cohort were enriched for bona fide Spitz melanomas, the majority of melanomas fell outside of the genetically defined category of Spitz melanomas, indicating that histomorphology is an unreliable predictor of Spitz lineage.

摘要

具有与 Spitz 痣重叠的组织病理学特征的黑色素瘤被称为 Spitz 样黑色素瘤。然而,该诊断概念的应用并不一致,且基因组分析表明其是一个异质性类别。Spitz 肿瘤,即从 Spitz 痣到其恶性对应物 Spitz 黑色素瘤的黑素细胞肿瘤谱,在 2018 年 WHO 皮肤肿瘤分类中,通过存在特定的遗传改变来定义,例如激酶融合或 HRAS 突变。目前尚不清楚仅通过其组织病理学特征定义的“Spitz 样黑色素瘤”中有多少属于 Spitz 黑色素瘤或其他黑色素瘤亚型。我们收集了一家机构在 8 年内诊断的 25 例 Spitz 样黑色素瘤病例,并对 480 个与癌症相关的基因进行了高覆盖度 DNA 测序。对部分病例进行了全转录组 RNA 测序。只有 9 例(36%)具有 Spitz 黑色素瘤的特征性遗传改变,包括 HRAS 突变或涉及 BRAF、ALK、NTRK1 或 MAP3K8 的融合。其余病例分为存在 MAPK 激活突变和不存在 MAPK 激活突变的病例。既没有 Spitz 黑色素瘤特征性遗传改变,也没有 MAPK 激活突变的 Spitz 样黑色素瘤,其发病年龄较小,皮肤中 solar elastosis 较少,很少携带 TERT 启动子突变,且致病性突变负担低于具有非-Spitz MAPK-activating 突变的 Spitz 样黑色素瘤。鉴定出的 MAPK 激活突变影响非 V600 残基的 BRAF 以及 NRAS、MAP2K1/2、NF1 和 KIT,而 BRAF V600 突变,即 WHO 低 CSD 类别黑色素瘤中最常见的突变,完全不存在。虽然我们队列中的“Spitz 样黑色素瘤”富集了真正的 Spitz 黑色素瘤,但大多数黑色素瘤不属于遗传定义的 Spitz 黑色素瘤类别,这表明组织形态学不能可靠预测 Spitz 谱系。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验